hapabapa
A report from the U.S. FDA’s Office of Inspector General is calling into question the thoroughness of the agency’s accelerated approval process, and is using treatments from Sarepta Therapeutics (NASDAQ:SRPT) and Biogen (NASDAQ:BIIB) as examples.
The Sarepta and Biogen therapies